title: Expression of SOCS3 mRNA in bone marrow cells from CML patients associated with cytogenetic response to IFN-alpha.
abstract: Previously, we have demonstrated that constitutive expression of suppressor of cytokine signaling-3 (SOCS3) affects the sensitivity of chronic myelogenous leukemia (CML) cell lines to interferon-alpha (IFN-alpha). In the present study, we analyzed the expression of SOCS3 mRNA in bone marrow cells from patients with CML at diagnosis, with the aid of real-time polymerase chain reaction. SOCS3 mRNA expression in bone marrow cells from CML patients who responded well to IFN-alpha therapy was significantly lower than that in cells from healthy volunteers and patients who were resistant to IFN-alpha therapy. Methylation of SOCS3 promoter was absent in bone marrow cells from all CML patients examined. These results indicate that the expression of SOCS3 mRNA is inversely associated with the sensitivity to IFN-alpha both in vitro and in vivo and that differences in SOCS3 mRNA expression are not due to the methylation status of SOCS3 promoters.
authors.affiliation: First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Ehime 791-0295, Japan.
authors.forename: Kazuto
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Ikuya
authors.initials: I
authors.lastname: Sakai
authors.forename: Hirosi
authors.initials: H
authors.lastname: Narumi
authors.forename: Masaki
authors.initials: M
authors.lastname: Yasukawa
authors.forename: Kensuke
authors.initials: K
authors.lastname: Kojima
authors.forename: Yoko
authors.initials: Y
authors.lastname: Minamoto
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Fujisaki
authors.forename: Kazushi
authors.initials: K
authors.lastname: Tanimoto
authors.forename: Masamichi
authors.initials: M
authors.lastname: Hara
authors.forename: Akihiko
authors.initials: A
authors.lastname: Numata
authors.forename: Hisashi
authors.initials: H
authors.lastname: Gondo
authors.forename: Masuhiro
authors.initials: M
authors.lastname: Takahashi
authors.forename: Nobuharu
authors.initials: N
authors.lastname: Fujii
authors.forename: Kozo
authors.initials: K
authors.lastname: Masuda
authors.forename: Shigeru
authors.initials: S
authors.lastname: Fujita
mesh_terms: D001854:Bone Marrow Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D015973:Gene Expression Regulation, Leukemic / Q000187:drug effects; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology*; D008745:Methylation; D012333:RNA, Messenger / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D012097:Repressor Proteins / Q000032:analysis / Q000187:drug effects / Q000235:genetics*; D012680:Sensitivity and Specificity; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D014157:Transcription Factors / Q000032:analysis / Q000187:drug effects / Q000235:genetics*
chemical_list: D016898:Interferon-alpha; D012333:RNA, Messenger; D012097:Repressor Proteins; C106644:SOCS3 protein, human; D000071223:Suppressor of Cytokine Signaling 3 Protein; D050826:Suppressor of Cytokine Signaling Proteins; D014157:Transcription Factors